Pharma companies need comprehensive genomic information to drive successful precision medicine programs, but decisions are often made using only a fraction of the data available…about 10%. Genomenon delivers 100% of the data.
LATEST WEBINAR WITH INOZYME PHARMA
Locus-Specific Patient Databases for Rare Disease: A Computational Approach
An efficient and cost-effective natural history research solution for Pharma, ProdigyTM Patient Landscapes support the development of rare disease therapies by enhancing insights contained in retrospective and prospective health data. Using a powerful AI-driven approach, Genomenon delivers comprehensive and expert assessment of every patient in the published medical literature – in a fraction of the time.
ARTICLE | Comprehensive Genomic Landscape for ALS
Read the latest article in the Journal of Precision Medicine revealing the clinical and genetic complexity of ALS.
Genomenon identified all of the genomic drivers in TARDBP associated with ALS in just two weeks…a yield of 435% more than the number of disease-causing variants found in ClinVar
Comprehensive
Don’t miss anything – get insight into every genomic biomarker published in the medical literature
Evidence-Based
Every scientific assertion is supported by empirical evidence from the medical literature
NEW REPORT: Key Findings from the Genomic Landscape for ALS
Discover profound insights from Genomenon’s comprehensive ProdigyTM Genomic Landscape for ALS, and their impact on Pharma
Genomenon’s comprehensive and organized collection of genomic evidence significantly accelerated our work in several key steps along our development process.
Genomenon’s methodology improved the efficiency and completeness of our literature review process.